ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.128,06
0,00%
S&P 500
6.013,13
-1,71%
US Dollar vs BRL
5,71736
-0,26%
Bitcoin
95.650,01
-0,65%
Brent Oil
74,065
-0,05%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Aquestive Therapeutics Inc (AQST)

  7. Aquestive Therapeutics Inc (AQST) Notícias

AQST

Aquestive Therapeutics (AQST)

Aquestive Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AQST
DataHoraFonteTítuloCódigoCompanhia
20/02/202509:00GlobeNewswire Inc.Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
14/02/202520:12Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
12/02/202509:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AQSTAquestive Therapeutics Inc
12/02/202509:00GlobeNewswire Inc.Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual MeetingNASDAQ:AQSTAquestive Therapeutics Inc
04/02/202509:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
24/01/202518:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AQSTAquestive Therapeutics Inc
13/01/202509:00GlobeNewswire Inc.Aquestive Therapeutics Provides Business Update and Outlines Key 2025 ObjectivesNASDAQ:AQSTAquestive Therapeutics Inc
19/12/202410:00GlobeNewswire Inc.Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to FiveNASDAQ:AQSTAquestive Therapeutics Inc
02/12/202410:00GlobeNewswire Inc.Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
27/11/202418:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
14/11/202417:47Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
12/11/202410:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Two Upcoming Investor ConferencesNASDAQ:AQSTAquestive Therapeutics Inc
08/11/202419:31Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AQSTAquestive Therapeutics Inc
04/11/202418:36GlobeNewswire Inc.Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
25/10/202409:00GlobeNewswire Inc.Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American CollegeNASDAQ:AQSTAquestive Therapeutics Inc
24/10/202409:00GlobeNewswire Inc.Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
21/10/202409:00GlobeNewswire Inc.Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
02/10/202415:16Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
27/09/202409:30GlobeNewswire Inc.Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor DayNASDAQ:AQSTAquestive Therapeutics Inc
09/09/202409:15GlobeNewswire Inc.Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27thNASDAQ:AQSTAquestive Therapeutics Inc
14/08/202409:00GlobeNewswire Inc.Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™NASDAQ:AQSTAquestive Therapeutics Inc
06/08/202417:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AQSTAquestive Therapeutics Inc
06/08/202417:22GlobeNewswire Inc.Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
25/07/202409:00GlobeNewswire Inc.Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration StudyNASDAQ:AQSTAquestive Therapeutics Inc
23/07/202409:00GlobeNewswire Inc.Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
27/06/202409:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismNASDAQ:AQSTAquestive Therapeutics Inc
25/06/202409:00GlobeNewswire Inc.Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
18/06/202409:00GlobeNewswire Inc.Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024NASDAQ:AQSTAquestive Therapeutics Inc
12/06/202418:14Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:AQSTAquestive Therapeutics Inc
11/06/202413:35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AQST

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BRKM5
BRASKEM PNA
BOV
RNEW4
RENOVA PN
BOV
PDGR3
PDG REALT ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
BRAV3
Brava Energia ON
BOV
PRIO3
PETRORIO ON
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios